Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2008 3
2009 2
2010 4
2011 10
2012 3
2013 5
2014 7
2015 14
2016 12
2017 9
2018 7
2019 9
2020 10
2021 15
2022 22
2023 11
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

122 results

Results by year

Filters applied: . Clear all
Page 1
Using the genomic adjusted radiation dose (GARD) to personalize the radiation dose in nasopharyngeal cancer.
Leung Chiang C, Sik Kwan Chan K, Li H, Tong Ng W, Chung Hang Chow J, Cheuk Wai Choi H, On Lam K, Ho Fun Lee V, Kai Cheong Ngan R, Wing Mui Lee A, Eschrich SA, Torres-Roca JF, Wing Hon Wong J. Leung Chiang C, et al. Among authors: tong ng w. Radiother Oncol. 2024 Apr 16:110287. doi: 10.1016/j.radonc.2024.110287. Online ahead of print. Radiother Oncol. 2024. PMID: 38636709
Dosimetric parameters predict radiation-induced temporal lobe necrosis in nasopharyngeal carcinoma patients: A systematic review and meta-analysis.
Dong J, Ng WT, Wong CHL, Li JS, Bollen H, Chow JCH, Eisbruch A, Lee AWM, Lee VHF, Ng SP, Nuyts S, Smee R, Ferlito A. Dong J, et al. Among authors: ng wt. Radiother Oncol. 2024 Mar 26;195:110258. doi: 10.1016/j.radonc.2024.110258. Online ahead of print. Radiother Oncol. 2024. PMID: 38537680 Free article. Review.
Efficacy, safety, and correlative biomarkers of bintrafusp alfa in recurrent or metastatic nasopharyngeal cancer patients: a phase II clinical trial.
Chiang CL, Lam TC, Li JCB, Chan KSK, El Helali A, Lee YYP, Law LHT, Zheng D, Lo AWI, Kam NW, Li WS, Cheung AKW, Chow JCH, Chan SPC, Lai JWY, Lee SWM, Kong FS, Ng WT, Kwong DLW, Lee AWM. Chiang CL, et al. Among authors: ng wt. Lancet Reg Health West Pac. 2023 Sep 6;40:100898. doi: 10.1016/j.lanwpc.2023.100898. eCollection 2023 Nov. Lancet Reg Health West Pac. 2023. PMID: 37701718 Free PMC article.
The impact of the multi-disciplinary molecular tumour board and integrative next generation sequencing on clinical outcomes in advanced solid tumours.
El Helali A, Lam TC, Ko EY, Shih DJH, Chan CK, Wong CHL, Wong JWH, Cheung LWT, Lau JKS, Liu APY, Chan ASY, Loong HH, Lam STS, Chan GC, Lee VHF, Yuen KK, Ng WT, Lee AWM, Ma ESK. El Helali A, et al. Among authors: ng wt. Lancet Reg Health West Pac. 2023 Apr 28;36:100775. doi: 10.1016/j.lanwpc.2023.100775. eCollection 2023 Jul. Lancet Reg Health West Pac. 2023. PMID: 37547050 Free PMC article.
Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis.
Petit C, Lee A, Ma J, Lacas B, Ng WT, Chan ATC, Hong RL, Chen MY, Chen L, Li WF, Huang PY, Tan T, Ngan RKC, Zhu G, Mai HQ, Hui EP, Fountzilas G, Zhang L, Carmel A, Kwong DLW, Moon J, Bourhis J, Auperin A, Pignon JP, Blanchard P; MAC-NPC Collaborative Group. Petit C, et al. Among authors: ng wt. Lancet Oncol. 2023 Jun;24(6):611-623. doi: 10.1016/S1470-2045(23)00163-8. Lancet Oncol. 2023. PMID: 37269842
Proton Beam Radiation Therapy for Oropharyngeal Squamous Cell Carcinoma.
Mendenhall WM, Beitler JJ, Saba NF, Shaha AR, Nuyts S, Strojan P, Bollen H, Cohen O, Smee R, Ng SP, Eisbruch A, Ng WT, Kirwan JM, Ferlito A. Mendenhall WM, et al. Among authors: ng wt. Int J Part Ther. 2023 Apr 27;9(4):243-252. doi: 10.14338/IJPT-22-00030.1. eCollection 2023 Spring. Int J Part Ther. 2023. PMID: 37169005 Free PMC article. Review.
122 results